secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2022-04-08T23:59:59+00:00
Accession:  0001193125-22-100522
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics cuts 30% of workforce, appoints new CFO
--------------------------------------------------------------

- Workforce reduction of ~30% to focus capital on FX-322, FX-345, and MS program.
- Estimated $1.2M in future cash severance costs; majority implemented, remainder by July 31, 2022.
- Richard M. Mitrano appointed principal financial officer, succeeding Peter P. Pfreundschuh.
- Mitrano previously Vice President of Finance and Operations since July 2016.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/0001193125-22-100522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312522100522/d348577d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-100522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer